ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS

He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.